Inflarx Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Inflarx Contact Number

Contact InflaRx

Just Now Inflarx.de Show details

641 508 180

Headquarter: InflaRx N.V. Winzerlaer Str. 2 07745 Jena Germany Phone: +49 (0)3641 508 180. [email protected]inflarx.de. Visit us in Jena . InflaRx N.V. Munich Fraunhoferstraße 22

Category: Contact SupportShow more

InflaRx Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Show details

49 3641-508

Contact Email [email protected]inflarx.de Phone Number 49 3641-508-180 InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.

Founders: Renfeng Guo, Niels C. Riedemann M.D., Ph.D.

Category: Contact NumberShow more

Impressum InflaRx

2 hours ago Inflarx.de Show details

InflaRx N.V. Winzerlaer Str. 2 07745 Jena Germany Phone: +49-(0)3641-508180 Fax: +49-(0)3641-508181 Internet: www.inflarx.de E-Mail: [email protected]inflarx.de Managing Board: Prof. Niels C. Riedemann, Executive Director and CEO

Category: Contact NumberShow more

Inflarx Pharmaceuticals Inc Company Profile Ann Arbor

1 hours ago Dnb.com Show details

Inflarx Pharmaceuticals Inc is located in Ann Arbor, MI, United States and is part of the Health and Personal Care Stores Industry. Inflarx Pharmaceuticals Inc has 7 total employees across all of its locations and generates $743,428 in sales (USD). (Employees and Sales figures are modelled).

Category: Contact NumberShow more

Corporate Governance InflaRx

3 hours ago Inflarx.de Show details

800-225-5288

InflaRx EthicsPoint-Ethics Hotline Reporting (reports can be made by website or phone) inflarx.ethicspoint.com. Germany Toll-free Hotline Number: 0-800-225-5288. U.S. Toll-free Hotline Number: 1-(844) 884-0118

Category: Contact NumberShow more

Privacy Policy InflaRx

7 hours ago Inflarx.de Show details

641 508 180

InflaRx GmbH Winzerlaer Str. 2 07745 Jena Germany +49 (0) 3641 508 180 [email protected]inflarx.de https://www.inflarx.de . 2. Address and e-mail of the data protection officer . Our external data protection officer will be available to provide you with information on data protection at the following contact details: datenschutz süd GmbH. Wörthstraße 15

Category: Contact NumberShow more

InflaRx Company Profile Office Locations, Competitors

4 hours ago Craft.co Show details

InflaRx is a biopharmaceutical company developing new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.

Category: Contact NumberShow more

IFRX InflaRx N.V. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

The Company will also hold virtual 1X1 meetings. About InflaRx N.V.: InflaRx (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a…. JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (NASDAQ: IFRX

Category: Contact NumberShow more

Financial Information InflaRx

4 hours ago Inflarx.de Show details

InflaRx PFIC Annual Information Statement 2019. InflaRx PFIC Annual Information Statement 2018. The following list represents all InflaRx SEC filings and financial reports. Blank - iframes - sec filings. Select year: Filter filing type: All Form Types Annual Filings Quarterly Filings Current Reports Proxy Filings Registration Statements Section

Category: Contact NumberShow more

InflaRx N.V. LinkedIn

4 hours ago Linkedin.com Show details

InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI USA. LinkedIn InflaRx N.V. in Worldwide

Category: Contact NumberShow more

InflaRx Company Profile: Stock Performance & Earnings

7 hours ago Pitchbook.com Show details

InflaRx General Information Description. InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a.

Category: Contact NumberShow more

062018InflaRx Opens New Research Facility in Ann Arbor

4 hours ago Inflarx.de Show details

49 3641 5081

InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”. For further information please visit www.inflarx.com. Contacts: InflaRx N.V. Prof. Dr. Niels C. Riedemann, CEO info[at]inflarx.de +49 3641 508180 . Arnd Christ, CFO

Category: Contact NumberShow more

Events & Presentations InflaRx

5 hours ago Inflarx.de Show details

641 508 180

InflaRx N.V. Winzerlaer Str. 2 07745 Jena . +49 (0)3641 508 180. [email protected]inflarx.de

Category: Contact NumberShow more

InflaRx N.V. (IFRX) Company Profile & Facts Yahoo Finance

5 hours ago Finance.yahoo.com Show details

See the company profile for InflaRx N.V. (IFRX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their

Category: Contact NumberShow more

Clinical Trials Register

2 hours ago Clinicaltrialsregister.eu Show details

11.Received > 3 g cumulative intravenous GCs within 4 weeks before screening. 12.a.Received an oral daily dose of a GC of > 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening. b.Received an oral daily dose of a GC of > 80 mg prednisone equivalent within 2 …

Category: Contact NumberShow more

Clinical Trials Register

2 hours ago Clinicaltrialsregister.eu Show details

Clinical trials. Print Download. A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa. Efficacy and safety study of a monoclonal antibody to treat patients with moderate to severe hidradenitis suppurativa (HS).

Category: Contact NumberShow more

102021InflaRx Completes Enrollment of Vilobelimab Phase

4 hours ago Inflarx.de Show details

10-2021-InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19. Study has enrolled 369 patients across 9 countries. Topline results expected to be available in Q1 2022. Jena, Germany, October 12, 2021 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by

Category: Contact NumberShow more

Noncomparative Study of IFX1 Alone or IFX1

7 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04812535

Category: Contact NumberShow more

InflaRx NV Company Profile and News Bloomberg Markets

9 hours ago Bloomberg.com Show details

Company profile page for InflaRx NV including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

InflaRx to Present at Upcoming Investor Conferences

1 hours ago Finance.yahoo.com Show details

For further information please visit www.inflarx.com. Contacts: InflaRx N.V.Jordan Zwick – Chief Strategy OfficerEmail: [email protected]inflarx.deTel: +1 …

Category: Contact NumberShow more

InflaRx Reports Full Year 2020 Financial & Operating Results

1 hours ago Finance.yahoo.com Show details

917-338-6523

Contacts: InflaRx N.V.Jordan Zwick – Chief Strategy OfficerEmail: [email protected]inflarx.deTel: +1 917-338-6523 MC Services AGKatja Arnold, Laurie Doyle, Andreas Jungfer Email: inflarx@mc-services.eu Europe

Category: Contact NumberShow more

Yong Li, Ph.D. Research Director InflaRx

9 hours ago Linkedin.com Show details

020-09-17

Research Director at InflaRx Pharmaceuticals Inc, a subsidiary of InflaRx N.V. (NASDAQ:IFRX) U.S. patent application number 16/784951, published on 2020-09-17 Contact Yong directly

Title: Research Director at InflaRx
Location: Ann Arbor, Michigan
Connections: 196

Category: Contact NumberShow more

Tony Gibney Joins InflaRx Board of Directors

7 hours ago Finance.yahoo.com Show details

For further information please visit www.inflarx.com. Contacts: InflaRx N.V.Jordan Zwick – Chief Strategy OfficerEmail: [email protected]inflarx.deTel: +1 …

Category: Contact NumberShow more

InflaRx to Proceed with Pivotal Development for

8 hours ago Stocktitan.net Show details

917-338-6523

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com. Contacts: InflaRx N.V. Jordan Zwick – Chief Strategy Officer Jason Stewart – Investor Relations Email: [email protected]inflarx.de Tel: +1 917-338-6523 . MC Services AG

Category: Contact NumberShow more

Clinical Trials Register

1 hours ago Clinicaltrialsregister.eu Show details

EudraCT number. 2020-001236-10. A.3. Full title of the trial. COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in Covid19 – a randomized, double --blind, placebo controlled, clinical trial in patients with severe Covid19 disease’. Effecten van imatinib bij patiënten met longschade door COVID-19 infectie.

Category: Contact NumberShow more

INFLARX N.V. : Shareholders Board Members Managers and

2 hours ago Marketscreener.com Show details

INFLARX N.V. : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information Nasdaq: IFRX Nasdaq

Category: Contact NumberShow more

InflaRx N.V. (IFRX) Stock Price, Quote & News Stock Analysis

8 hours ago Stockanalysis.com Show details

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of …

Category: Contact NumberShow more

Niels C. Riedemann, Chief Executive Officer & Founder at

4 hours ago Relationshipscience.com Show details

Number of Boards. 2. Birthday. 12/1972. Age. 46. Contact Data. Trying to get in touch with Niels C. Riedemann? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits! InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and

Category: Contact NumberShow more

InflaRx Announces Positive Data from Second Interim

3 hours ago Benzinga.com Show details

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit www.inflarx.com . …

Category: Contact NumberShow more

InflaRx N.V. (IFRX): The long term indicators on the stock

5 hours ago Baxterreport.com Show details

InflaRx N.V. (IFRX) saw an uptrend of 13.50% in the recent trading with $2.69 being its most recent. The current price level -60.90% lower than the highest price of $6.88 marked by the stock while trading over the past 52-weeks, whereas it is 20.63% higher than the lowest price of $2.23 the company dropped to over past 52-weeks.

Category: Contact NumberShow more

InflaRx N : to Proceed with Pivotal Development for

7 hours ago Marketscreener.com Show details

Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.

Category: Contact NumberShow more

InflaRx Reports First Quarter 2021 Financial & Operating

Just Now Finance.yahoo.com Show details

For further information please visit www.inflarx.com. Contacts: InflaRx N.V. Jordan Zwick – Chief Strategy OfficerEmail: [email protected]inflarx.deTel: …

Category: Contact NumberShow more

InflaRx Reports Q2 2020 Financial & Operating Results

9 hours ago Finance.yahoo.com Show details

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. Forward-looking statements appear in …

Category: Contact NumberShow more

InflaRx Reports Q3 2020 Financial & Operating Results

9 hours ago Finance.yahoo.com Show details

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. Forward-looking statements appear in …

Category: Contact NumberShow more

Coronavirus Treatment: Biotech Companies Gilead, InflaRx

5 hours ago Investors.com Show details

But that comes alongside a number of delays for several other programs. The news sent InflaRx stock rocketing 50%, to 5.73, in hefty volume . BioNTech stock, …

Category: Tech SupportShow more

InflaRx N : Voting Proxy EGM 2021 MarketScreener

Just Now Marketscreener.com Show details

The Principal hereby registers for the extraordinary general meeting of shareholders of InflaRx N.V. (the "Company ") to be held on August 25, 2021 at 9:00 hours CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the " EGM ") and, for purposes of being represented at the EGM, grants a power of

Category: Contact NumberShow more

INFLARX N : Form 6K) MarketScreener

7 hours ago Marketscreener.com Show details

Inflarx NV published this content on 15 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and …

Category: Contact NumberShow more

InflaRx N.V. (IFRX): The long term indicators on the stock

3 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 44.19 million. IFRX does have institutional investors; and they hold 25.70% of the stock. InflaRx N.V. – Insider Activity and Holdings. Currently, the stock has been recommended as Moderate Buy by 6 of the brokerage firms.

Category: Contact NumberShow more

InflaRx N : 092021InflaRx to Proceed with Pivotal

7 hours ago Marketscreener.com Show details

Jena, Germany, September 8, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces its plan to proceed with a pivotal development program for vilobelimab in Hidradenitis Suppurativa (HS) after a successful Type A meeting with the US Food and Drug Administration (FDA) …

Category: Contact NumberShow more

Efficacy and Safety Study of IFX1 in Patients With

7 hours ago Clinicaltrials.gov Show details

The absolute change from Day 1 will be analyzed by descriptive statistics by time point. The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters.

Category: Contact NumberShow more

InflaRx N.V. (IFRX) company profile & facts – Yahoo Finance

8 hours ago Uk.finance.yahoo.com Show details

See the company profile for InflaRx N.V. (IFRX), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information.

Category: Contact NumberShow more

It’s Worth A Gamble To Have A Position In InflaRx N.V

4 hours ago Marketingsentinel.com Show details

InflaRx N.V. (NASDAQ:IFRX)’s traded shares stood at 1.79 million during the latest session, with the company’s beta value hitting 0.44. At the last check today, the stock’s price was $2.53, to imply an increase of 6.67% or $0.16 in intraday trading. The IFRX share’s 52-week high remains $6.8

Category: Contact NumberShow more

Exploratory Study of IFX1 in Subjects With Pyoderma

7 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03971643

Category: Contact NumberShow more

Inflarx NV (IFRX) Stock:Do Analysts Think You Should Buy?

5 hours ago Investorsobserver.com Show details

Inflarx NV (IFRX) stock is lower by -3.02% while the S&P 500 has risen 0.72% as of 11:13 AM on Friday, Jul 23. IFRX has fallen -$0.08 from the previous closing price …

Category: Contact NumberShow more

InflaRx to Present at Upcoming Virtual Investor Events

6 hours ago Globenewswire.com Show details

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit www.inflarx.com . …

Category: Contact NumberShow more

InflaRx N.V. (IFRX): The stock’s intermediateterm

5 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 44.19 million. IFRX does have institutional investors; and they hold 25.70% of the stock. InflaRx N.V. – Insider Activity and Holdings. Currently, the stock has been recommended as Moderate Buy by 6 of the brokerage firms.

Category: Contact NumberShow more

InflaRx Full Year 2018 Financial & Operating Results

2 hours ago Globenewswire.com Show details

InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, …

Category: Contact NumberShow more

InflaRx N : 092021InflaRx to Present at the H.C

6 hours ago Marketscreener.com Show details

Jena, Germany, September 9, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Officer and Founder, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being …

Category: Contact NumberShow more

InflaRx Completes Enrollment of Vilobelimab Phase III

2 hours ago Finance.yahoo.com Show details

2 days ago · Study has enrolled 369 patients across 9 countriesTopline results expected to be available in Q1 2022 JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Intel
Icbc
Imcd
Iqvia
Idex
Isbank
Ing
Intuit
Itc
Ipg